Kelly Seaton, Ph.D.
Affiliations: | 2009 | Pennsylvania State University, State College, PA, United States |
Area:
Pharmacology, Virology BiologyGoogle:
"Kelly Seaton"Mean distance: 42746.4
Parents
Sign in to add mentor| Jong K. Yun | grad student | 2009 | Penn State | |
| (The human N-myristoyltransferases as potential pharmacotherapeutic targets in HIV-1 replication.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Walsh SR, Gay CL, Karuna ST, et al. (2024) A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087). Medrxiv : the Preprint Server For Health Sciences |
| Reeves DB, Mayer BT, deCamp AC, et al. (2023) High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nature Communications. 14: 8299 |
| Sobieszczyk ME, Mannheimer S, Paez CA, et al. (2023) Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial. The Lancet. Hiv. 10: e653-e662 |
| Chirenje ZM, Laher F, Dintwe O, et al. (2023) Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120. The Journal of Infectious Diseases |
| Tieu HV, Karuna S, Huang Y, et al. (2023) Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US. Vaccine |
| Seaton KE, Huang Y, Karuna S, et al. (2023) Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. Ebiomedicine. 93: 104590 |
| Huang Y, Zhang Y, Seaton KE, et al. (2022) Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens. Ebiomedicine. 84: 104271 |
| Gilbert PB, Huang Y, deCamp AC, et al. (2022) Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nature Medicine |
| Moodie Z, Dintwe O, Sawant S, et al. (2022) Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk. The Journal of Infectious Diseases |
| Tomalka JA, Pelletier AN, Fourati S, et al. (2021) The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. Nature Immunology |